Related Experiment Video
Updated: Mar 23, 2026

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
Published on: December 30, 2025
[PLACE REMAXOL AS A HEPATOPROTECTOR IN INTENSIVE THERAPY OF PERVASIVE PERITONITIS]
Remaxol effectively treated pervasive peritonitis by improving hemodynamics and reducing metabolic disorders. This led to shorter respiratory support and earlier nutritional intake, demonstrating its therapeutic benefits.
Area of Science:
- Critical care medicine
- Pharmacology
- Gastroenterology
Context:
- Peritonitis is a severe condition requiring intensive management.
- Early and effective treatment is crucial for patient outcomes.
- Hepatic dysfunction and endotoxemia are common complications.
Purpose:
- To evaluate the efficacy of Remaxol in patients with pervasive peritonitis.
- To assess Remaxol's impact on metabolic disorders, endotoxemia, and hepatic dysfunction.
- To determine Remaxol's effect on systemic hemodynamics and oxygen transport.
Summary:
- Remaxol infusion (800 mg/day for 7 days) was administered to 21 peritonitis patients.
- Compared to a control group, Remaxol patients showed faster relief of metabolic disorders and endotoxemia.
- Earlier stabilization of hemodynamics and oxygen transport was observed in the Remaxol group.
Impact:
- Remaxol use resulted in reduced duration of respiratory and vasopressor support.
- Early initiation of parenteral nutrition was facilitated by Remaxol treatment.
- The study highlights Remaxol's role in managing hepatic dysfunction and preventing liver toxicity in peritonitis.
Related Concept Videos
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

